Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51

BACKGROUND: Chemotherapy is a standard therapeutic regimen to treat triple-negative breast cancer (TNBC); however, chemotherapy alone does not result in significant improvement and often leads to drug resistance in patients. In contrast, combination therapy has proven to be an effective strategy for...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jung Ok, Kang, Min Ju, Byun, Won Seok, Kim, Shin Ae, Seo, Il Hyeok, Han, Jeong Ah., Moon, Ji Wook, Kim, Ji Hae, Kim, Su Jin, Lee, Eun Jung, In Park, Serk, Park, Sun Hwa, Kim, Hyeon Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805313/
https://www.ncbi.nlm.nih.gov/pubmed/31640742
http://dx.doi.org/10.1186/s13058-019-1204-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805313/
https://www.ncbi.nlm.nih.gov/pubmed/31640742
http://dx.doi.org/10.1186/s13058-019-1204-2

Ejemplares similares